PROTEINTECH-GROUP
20.3.2024 19:58:26 CET | Business Wire | Press release
Proteintech, the benchmark in antibodies and life science solutions, announces that its branch in Martinsried near Munich has moved into its new laboratory and office space. The new building houses research and development, production, logistics and administration in an area more than three times larger than its previous space.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240320643097/en/
Proteintech celebrates the opening with a ribbon cutting event. Pictured: Dr. Jason Li, CEO of Proteintech, along with Proteintech executives and local government officials. (Photo: Business Wire)
In 2020, the Proteintech Group acquired ChromoTek GmbH, which specializes in the development and production of Nanobody-based reagents and was located at the incubator IZB. The gradual integration of Chromotek into the parent company, Proteintech Group, enabled new sales markets and channels for the products manufactured in Martinsried. The Martinsried site also serves as a central logistics hub for all Proteintech products for customers in the European Union.
Rainer Gebhart, Site Manager at Proteintech Germany, said: “Here we offer state-of-the-art working environments for daily top performance and innovation of our employees - our most important capital for a continued successful future.” He also explained, “The move supports our customer focused strategy. With a larger team in Martinsried – and in cooperation with our sister site in Manchester, UK – we can better serve our customers in Europe and further gain market share.”
Dr Jason Li, CEO of Proteintech said, “There is a great future for Nanobody technology and we’re excited to be at the forefront of this.” He also stated, “Proteintech has R&D and production laboratories on three continents in its major sites (Chicago, Wuhan and Martinsried). All three sites have seen expansion in the past year and the collaboration between them means we can bring new and innovative products to the market.”
About Proteintech Group
Proteintech Group Inc., founded in 2001, is a leading manufacturer of antibodies, proteins, nanobodies, and immunoassays. Proteintech has the largest proprietary portfolio of self-manufactured antibodies covering 2/3 of the human proteome. Proteintech offers antibodies, proteins and immunoassays across research areas with over 200,000 products cited. In addition, Proteintech produces cytokines, growth factors and other proteins that are human expressed, bioactive and cGMP-grade. Proteintech sites are ISO13485 and ISO9001 accredited.
To learn more about Proteintech, please visit www.ptglab.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240320643097/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TACTICAAI and NVIDIA Collaborate to Scale Agentic AI Capabilities with NVIDIA Nemotron22.10.2026 12:01:00 CEST | Press release
Collaboration brings together TACTICAAI’s operational decision-intelligence technology and NVIDIA AI capabilities to advance reasoning, autonomous analysis and video intelligence for real-world deployment TACTICAAI, an operational decision-intelligence company, today announced a collaboration with NVIDIA to advance and scale the deployment of agentic AI capabilities. The companies will work together to integrate and optimize NVIDIA Nemotron models within TACTICAAI’s multi-intelligence platform, with a focus on expanding these capabilities and supporting deployment with major customers internationally. The collaboration was announced at NVIDIA GTC Berlin. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022054475/en/ TACTICA AI and NVIDIA Collaborate to Scale Agentic AI Capabilities with NVIDIA Nemotron (Graphic: AETOSWire) The collaboration with NVIDIA builds on the company’s existing technology, integrating selected NVIDIA
BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 522.10.2026 12:01:00 CEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its third quarter 2026 financial results on Thursday, November 5, 2026, before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com.To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has
Bregal Milestone Backs Nethive With Majority Growth Investment and JoyComm Acquisition22.10.2026 10:00:00 CEST | Press release
Partnership to support Nethive’s next phase of growth as a leading cybersecurity services and software platform Bregal Milestone, a leading European software growth private equity firm, today announced a majority growth investment in Nethive S.p.A. (“Nethive” or the “Company”), a leading Italian cybersecurity services and software provider. Alongside its investment in Nethive, Bregal Milestone has also backed Nethive’s acquisition of IT security specialist Joy Comm S.r.l. (“JoyComm”). Founded in 2014 by Alessandro Bellato and Diego Rocco, Nethive has become a trusted cybersecurity partner to blue-chip enterprises, SMEs, and public-sector organizations across Italy. Its platform spans managed security services, professional services and technology resale, helping organizations protect critical infrastructure and networks, strengthen cyber resilience and reduce operational complexity. Nethive combines deep technical expertise with 24/7 monitoring, threat detection and response, risk and
EOS and VOP CZ Sign Memorandum of Understanding to Explore Cooperation on Czech Programmes22.10.2026 09:00:00 CEST | Press release
EOS Defence Systems (EOS) and VOP CZ have signed a Memorandum of Understanding (MoU) at Future Forces Forum in Prague to explore cooperation on wheeled armoured vehicle programmes for the Czech Army and other future defence projects in the Czech Republic and Europe where VOP CZ is involved. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021408045/en/ EOS and VOP CZ sign a Memorandum of Understanding at Future Forces Forum in Prague. Left to right: Martin van de Voorde, Sales Director Europe, EOS; Vlastimil Navrátil, Managing Director, VOP CZ; Pavla Ungrová, Sales Director, VOP CZ; Rear Admiral Richard Caton, Australia’s Military Representative to NATO and the EU; Group Captain Michael Schleeman, Australia’s Defence Attaché; and Matej Pupák, Program Lead, VOP CZ. The agreement brings together EOS' expertise in advanced remote weapon systems (RWS) with VOP CZ's established capabilities in military vehicle integration, produ
Ferrer and Prilenia Announce Authorization for EU Initiation of Confirmatory PRECISE-HD Study of Pridopidine in Huntington's Disease22.10.2026 09:00:00 CEST | Press release
Ferreri and Prilenia Therapeutics B.V.today announced that the confirmatory Phase 3 PRECISE-HD study of investigational pridopidine in Huntington's disease (HD) has received authorization to begin in participating EU Member States (EU CT number: 2026-526093-16-00, NCT07609108). Recruitment in the EU is expected to commence this month, joining currently recruiting sites in the US and UK, with Canada to follow. Designed to evaluate the efficacy and safety of pridopidine (administered as an oral capsule twice a day), and to generate data for regulatory evaluation, the global, approximately 400-participant, randomized, double-blind, placebo-controlled PRECISE-HD study will assess the clinical effect of the investigational treatment on disease progression, functional capacity, motor function, cognition, speech and quality of life. “The initiation of PRECISE-HD in Europe marks a milestone for the Huntington’s disease research community. This confirmatory Phase 3 study has been designed to bu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom